|
CFT8634
|
C608488-10mg
|
Moligand™, ≥98% |
2704617-96-7 |
10mg
|
¥ 4443.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
头孢吡普
|
C608465-1mg
|
Moligand™, ≥98% |
209467-52-7 |
1mg
|
¥ 399.9
|
现货 |
|
0 |
阿拉丁 |
|
Bz(4-F)-Arg-Arg-2Nal-Cys(1)-Tyr-D-Cit-Lys-D-Lys-Pro-Tyr-Arg-Cit-Cys(1)-Arg-NH2
|
B671376-1mg
|
|
N/A |
1mg
|
¥ 2999.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
BMS-509744
|
B608130-50mg
|
Moligand™, ≥98% |
439575-02-7 |
50mg
|
¥ 7599.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
BMS-509744
|
B608130-1mg
|
Moligand™, ≥98% |
439575-02-7 |
1mg
|
¥ 269.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
BMS-509744
|
B608130-10mg
|
Moligand™, ≥98% |
439575-02-7 |
10mg
|
¥ 1899.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
binodenoson
|
B608093-1mg
|
Moligand™, ≥95% |
144348-08-3 |
1mg
|
¥ 1099.9
|
现货 |
|
0 |
阿拉丁 |
|
binodenoson
|
B608093-10mg
|
Moligand™, ≥95% |
144348-08-3 |
10mg
|
¥ 4299.9
|
现货 |
|
0 |
阿拉丁 |
|
BAY-73-1449
|
B607951-50mg
|
Moligand™, ≥97% |
693790-96-4 |
50mg
|
¥ 7999.9
|
现货 |
|
0 |
阿拉丁 |
|
BAY-73-1449
|
B607951-1mg
|
Moligand™, ≥97% |
693790-96-4 |
1mg
|
¥ 899.9
|
现货 |
|
0 |
阿拉丁 |
|
BAY-73-1449
|
B607951-10mg
|
Moligand™, ≥97% |
693790-96-4 |
10mg
|
¥ 3699.9
|
现货 |
|
0 |
阿拉丁 |
|
BAY-73-1449
|
B607951-100mg
|
Moligand™, ≥97% |
693790-96-4 |
100mg
|
¥ 10999.9
|
现货 |
|
0 |
阿拉丁 |
|
BAY-545
|
B607946-1mg
|
Moligand™, ≥98% |
1699717-32-2 |
1mg
|
¥ 899.9
|
现货 |
|
0 |
阿拉丁 |
|
BAY-545
|
B607946-10mg
|
Moligand™, ≥98% |
1699717-32-2 |
10mg
|
¥ 4199.9
|
现货 |
|
0 |
阿拉丁 |
|
Boc-Val-Cit-PAB
|
B597026-100mg
|
≥97% |
870487-09-5 |
100mg
|
¥ 629.9
|
现货 |
|
0 |
阿拉丁 |
|
Boc-Val-Cit-OH
|
B597025-5g
|
≥95% |
870487-08-4 |
5g
|
¥ 399.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Boc-Val-Cit-OH
|
B597025-25g
|
≥95% |
870487-08-4 |
25g
|
¥ 1899.9
|
现货 |
|
0 |
阿拉丁 |
|
双-PEG10-琥珀酰亚胺酯
|
B596578-25mg
|
≥98% |
2221949-02-4 |
25mg
|
¥ 699.9
|
现货 |
|
0 |
阿拉丁 |
|
Vonlerolizumab (anti-OX40)
|
Ab175702-10mg
|
科研级, Moligand™, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
1638935-72-4 |
10mg
|
¥ 9399.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Trastuzumab emtansine (anti-ERBB2)
|
Ab175686-10mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
1018448-65-1 |
10mg
|
¥ 22229.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Tisotumab vedotin (anti-Tissue Factor)
|
Ab175681-10mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
1418731-10-8 |
10mg
|
¥ 30299.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Rovelizumab (anti-CD11a&CD18)
|
Ab175649-10mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
339086-79-2 |
10mg
|
¥ 13839.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Ozoralizumab (anti-TNF-alpha&HSA)
|
Ab175623-10mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
1167985-17-2 |
10mg
|
¥ 15199.9
|
期货,请咨询 |
|
0 |
阿拉丁 |
|
Lifastuzumab vedotin (anti-SLC34A2)
|
Ab175578-10mg
|
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
1401812-88-1 |
10mg
|
¥ 30299.9
|
期货,请咨询 |
|
0 |
阿拉丁 |